Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2016-07-27

Original market date: See footnote 1

2016-07-27

Product name:

SANDOZ MOMETASONE

Description:

SUSPENSION

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02449811

Product Monograph/Veterinary Labelling:

Date: 2018-03-07 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

SANDOZ CANADA INCORPORATED
110 Rue De Lauzon
Boucherville
Quebec
Canada  J4B 1E6

Class: 

Human

Dosage form(s):

Spray, Metered Dose

Route(s) of administration:

Nasal

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

52:08.08   CORTICOSTEROIDS

Anatomical Therapeutic Chemical (ATC): See footnote 4

R01AD09  MOMETASONE

Active ingredient group (AIG) number:See footnote 5

0121732002

List of active ingredient(s)
Active ingredient(s) Strength
MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCG / ACT

Application information

Related information

Contact us

Version 3.8.0
Date modified: